ProQR Therapeutics N.V.
Status: Publicly traded
Direct answer
ProQR Therapeutics N.V. is publicly traded on NASDAQ under the ticker PRQR.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also...
Can you invest in ProQR Therapeutics N.V.?
Yes. ProQR Therapeutics N.V. trades publicly on NASDAQ as PRQR.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for ProQR Therapeutics N.V.
Detailed equity research is provided by MarketSnap.